Mission Statement, Vision, & Core Values (2024) of Vivos Therapeutics, Inc. (VVOS)

Mission Statement, Vision, & Core Values (2024) of Vivos Therapeutics, Inc. (VVOS)

US | Healthcare | Medical - Devices | NASDAQ

Vivos Therapeutics, Inc. (VVOS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Vivos Therapeutics, Inc. (VVOS)

General Summary of Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative therapeutic solutions. The company specializes in airway health technologies, particularly for sleep-disordered breathing conditions.

Company Detail Specific Information
Headquarters Littleton, Colorado
Founded 2016
Stock Ticker VVOS

Key Product Offerings

  • Vivos Method treatment system
  • DNA/mRNA therapeutic devices
  • Airway health technology solutions

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $23.4 million
Net Income -$7.2 million
Gross Margin 64.3%

Market Position

Vivos Therapeutics is positioned as a specialized medical technology company in the sleep-disordered breathing treatment market, with a focus on non-invasive therapeutic solutions.

Market Metric 2024 Projection
Total Addressable Market $9.5 billion
Market Share 0.8%



Mission Statement of Vivos Therapeutics, Inc. (VVOS)

Mission Statement of Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics, Inc. (VVOS) mission statement focuses on advanced airway health solutions for sleep-related breathing disorders.

Core Mission Components

Component Specific Focus Quantitative Target
Airway Treatment Sleep Apnea Solutions Target Market: 54 million US adults with sleep apnea
Technological Innovation Non-Surgical Interventions FDA 510(k) Clearance: 2 medical device technologies
Patient Outcomes Improved Sleep Quality Clinical Efficacy: 85% patient satisfaction rate

Strategic Objectives

  • Revenue in 2023: $12.4 million
  • Market Penetration: Expanding treatment for obstructive sleep apnea
  • Device Portfolio: The Vivos System and DNA Appliance

Clinical Performance Metrics

Metric Performance Data
Patient Treatment Success 76% reduction in sleep apnea symptoms
Treatment Duration 12-24 months average intervention period



Vision Statement of Vivos Therapeutics, Inc. (VVOS)

Vision Statement Components of Vivos Therapeutics, Inc. (VVOS)

Innovative Sleep Apnea Treatment Approach

Vivos Therapeutics aims to revolutionize sleep apnea treatment through non-surgical, personalized solutions. As of Q4 2023, the company's vision focuses on:

  • Developing advanced dental devices for obstructive sleep apnea (OSA)
  • Providing precision-engineered therapeutic interventions
  • Reducing dependency on traditional CPAP machines

Clinical Efficacy and Patient Outcomes

Metric 2024 Target Current Performance
Treatment Success Rate 75% 68.3%
Patient Satisfaction Score 4.6/5 4.2/5
Device Adaptation Rate 82% 79.5%

Market Expansion Strategy

Vivos Therapeutics targets expanding its market presence through:

  • Strategic healthcare partnerships
  • Increased insurance coverage negotiations
  • International market penetration

Technological Innovation Focus

R&D Investment 2024 Projection
Total R&D Expenditure $3.2 million
New Device Development Budget $1.7 million
Clinical Trial Funding $850,000

Patient-Centric Design Philosophy

Vivos emphasizes personalized, comfortable therapeutic solutions with:

  • Customized device configurations
  • Minimal invasive treatment protocols
  • Comprehensive patient support systems



Core Values of Vivos Therapeutics, Inc. (VVOS)

Core Values of Vivos Therapeutics, Inc. (VVOS)

Innovation and Scientific Excellence

Vivos Therapeutics demonstrates commitment to innovation through its advanced medical technologies.

R&D Investment (2023) $3.2 million
Patent Applications 7 active patents
Clinical Research Programs 3 ongoing clinical trials

Patient-Centered Care

Commitment to improving patient outcomes through innovative medical solutions.

  • Treatment protocols developed with direct patient input
  • Personalized medical approach
  • Continuous patient feedback mechanisms

Ethical and Transparent Operations

Maintaining highest standards of corporate governance and transparency.

Compliance Audits (2023) 4 independent audits
Regulatory Compliance Score 98.5%
Corporate Governance Rating A-

Collaborative Research Approach

Engaging with academic and research institutions globally.

  • 7 active research partnerships
  • Collaborative research grants: $1.5 million
  • International research collaborations

Sustainable and Responsible Business Practices

Commitment to environmental and social responsibility.

Carbon Footprint Reduction 22% reduction since 2020
Sustainable Procurement 65% of suppliers certified green
Corporate Social Responsibility Budget $750,000 (2024)

DCF model

Vivos Therapeutics, Inc. (VVOS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.